Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer

Int J Cancer. 1997 Feb 20;74(1):138-40. doi: 10.1002/(sici)1097-0215(19970220)74:1<138::aid-ijc23>3.0.co;2-a.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibiotics, Antineoplastic / therapeutic use*
  • Biomarkers
  • Breast Neoplasms / blood supply*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Doxorubicin / therapeutic use*
  • Female
  • Follow-Up Studies
  • Genes, p53
  • Humans
  • Immunohistochemistry
  • Middle Aged
  • Mutation
  • Neoplasm Staging
  • Neovascularization, Pathologic*
  • Predictive Value of Tests
  • Tumor Suppressor Protein p53 / analysis
  • Tumor Suppressor Protein p53 / genetics
  • von Willebrand Factor / analysis

Substances

  • Antibiotics, Antineoplastic
  • Biomarkers
  • Tumor Suppressor Protein p53
  • von Willebrand Factor
  • Doxorubicin